BMSSC
APLS

B. Metzler seel. Sohn & Co’s Apellis Pharmaceuticals APLS Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,338
Closed -$668K – 727
2023
Q2 		$668K Buy
+7,338
New +$633K 0.01% 547

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

B. Metzler seel. Sohn & Co's APLS Position: Q3 2023 in Review

B. Metzler seel. Sohn & Co sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 7,338 shares — an estimated $668K sold.

B. Metzler seel. Sohn & Co first reported a position in APLS in Q2 2023 and held it in 1 quarter. The position peaked at $668K in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • B. Metzler seel. Sohn & Co reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 7,338 Apellis Pharmaceuticals shares in Q3 2023, an estimated $668K.
  • B. Metzler seel. Sohn & Co first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • B. Metzler seel. Sohn & Co's Apellis Pharmaceuticals position peaked at $668K in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q3 2023, filed 13 Nov 2023.